This Article  • PDF of this Correction  • Original article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2007;298(9):973.

Incorrect Data and Wording: The Original Contribution entitled "Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial" published in the June 21, 2006, issue of JAMA (2006;295[23]:2742-2751) reported incorrect data and included incorrect wording. One page 2746, in Figure 1, the P value for the SF-36 Mental Component Summary should have been .14 and for the SF-36 Physical Component Summary, the P value should have been .23. On the same page the P values should have been reported similarly in text: "(P=.14, MCS and P=.23, PCS)." Also, on the same page, the text that read "Forms were not expected after death or consent withdrawal, which occurred at some point during follow-up for 197 women (1.0%) in the tamoxifen and 1352 (6.8%) in the raloxifene groups" should have read "Forms were not expected from the 207 women (1.0%) who died or from the 1352 women (6.8%) who withdrew consent at some point during follow-up."